Change search
ReferencesLink to record
Permanent link

Direct link
Genetic variants in the LEPR, CRY1, RNASEL, IL4, and ARVCF genes are prognostic markers of prostate cancer-specific mortality
Department of Urology, University of Washington School of Medicine, Seattle, WA.
Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, WA.
Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, WA; Department of Biostatistics, University of Washington, Seattle, WA.
Cancer Genetics Branch, National Human Genome Research Institute, NIH, Bethesda, MD.
Show others and affiliations
2011 (English)In: Cancer Epidemiology, Biomarkers and Prevention, ISSN 1055-9965, E-ISSN 1538-7755, Vol. 20, no 9, 1928-1936 p.Article in journal (Refereed) Published
Abstract [en]

Background: Prostate cancer is the second leading cause of cancer-related deaths in men, accounting for more than 30,000 deaths annually. The purpose of this study was to test whether variation in selected candidate genes in biological pathways of interest for prostate cancer progression could help distinguish patients at higher risk for fatal prostate cancer.

Methods: In this hypothesis-driven study, we genotyped 937 single nucleotide polymorphisms (SNPs) in 156 candidate genes in a population-based cohort of 1,309 prostate cancer patients. We identified 22 top-ranking SNPs (P <= 0.01, FDR <= 0.70) associated with prostate cancer-specific mortality (PCSM). A subsequent validation study was completed in an independent population-based cohort of 2,875 prostate cancer patients.

Results: Five SNPs were validated (P <= 0.05) as being significantly associated with PCSM, one each in the LEPR, CRY1, RNASEL, IL4, and ARVCF genes. Compared with patients with 0 to 2 of the at-risk genotypes those with 4 to 5 at-risk genotypes had a 50% (95% CI, 1.2-1.9) higher risk of PCSM and risk increased with the number of at-risk genotypes carried (P(trend) = 0.001), adjusting for clinicopathologic factors known to influence prognosis.

Conclusion: Five genetic markers were validated to be associated with lethal prostate cancer.

Impact: This is the first population-based study to show that germline genetic variants provide prognostic information for prostate cancer-specific survival. The clinical utility of this five-SNP panel to stratify patients at higher risk for adverse outcomes should be evaluated. Cancer Epidemiol Biomarkers Prev; 20(9); 1928-36. (C)2011 AACR.

Place, publisher, year, edition, pages
Philadelphia: American Association for Cancer Research , 2011. Vol. 20, no 9, 1928-1936 p.
National Category
Cancer and Oncology
URN: urn:nbn:se:umu:diva-47658DOI: 10.1158/1055-9965.EPI-11-0236ISI: 000294609200016OAI: diva2:445279
Available from: 2011-10-03 Created: 2011-09-27 Last updated: 2011-10-03Bibliographically approved

Open Access in DiVA

No full text

Other links

Publisher's full text

Search in DiVA

By author/editor
Stattin, Paer
By organisation
Department of Surgical and Perioperative Sciences
In the same journal
Cancer Epidemiology, Biomarkers and Prevention
Cancer and Oncology

Search outside of DiVA

GoogleGoogle Scholar
The number of downloads is the sum of all downloads of full texts. It may include eg previous versions that are now no longer available

Altmetric score

Total: 23 hits
ReferencesLink to record
Permanent link

Direct link